Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

Who Took Part

The study group was 26 patients.

How the Study Was Run

The design is described as randomized and placebo-controlled.

The patients were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Some patients received a placebo instead of Semaglutide, giving a reference point.

Adverse events (AEs) were analysed descriptively.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Hypoglycemic Agents, Japan and Semaglutide.

The authors tagged it with the keywords Glucagon-like peptide-1 receptor agonist, Japanese, PIONEER, oral semaglutide, post hoc and subgroup analyses.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Semaglutide in 26 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.